Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 4/20 | 0.47 |
| ▸ | SKP1 | P63208 | 4/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362961 | 0.90 | GPR119 (0.41) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL361367 | 0.87 | CKS1B (0.47) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL361713 | 0.85 | CKS1B (0.45) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL363214 | 0.85 | CKS1B (0.45) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL361644 | 0.85 | CKS1B (0.45) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL361221 | 0.83 | CKS1B (0.38) | CKS1BSKP1SKP2 | |
| SCHEMBL360863 | 0.82 | CKS1B (0.43) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL361792 | 0.79 | CKS1B (0.45) | CKS1BSKP1SKP2USP30GPR119 | |
| SCHEMBL15110449 | 0.78 | GPR119 (0.41) | CKS1BSKP1SKP2GPR119KDM1A | |
| SCHEMBL14876636 | 0.75 | KDM1A (0.38) | KDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9115129-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20140357642-A1 | IP receptor agonist heterocyclic compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2802585-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| WO-2013105065-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357642-A1 | IP receptor agonist heterocyclic compounds | PTGIR, GPR68, GPR84 | CKS1B 2434/4885SKP1 4178/4885SKP2 3149/4885 |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | CKS1B 2862/4885SKP1 3883/4885SKP2 3562/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | CKS1B 2862/4885SKP1 3883/4885SKP2 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.